What Researchers Did
Researchers gave hyperbaric oxygen to 19 patients with brain metastases just before stereotactic radiosurgery and compared them with 19 matched historical controls to check feasibility, safety and response.
What They Found
In this small non-randomised study of 38 patients, adding hyperbaric oxygen before radiosurgery was feasible and showed no significant difference from controls in radionecrosis-free survival, local recurrence-free survival, distant recurrence-free survival or overall survival. The HBO group had 25 brain metastases and the controls had 27. The average time from the HBO chamber to radiosurgery beam-on was 8.3 minutes, give or take 1.7. Reported side effects were comparable between groups, and no grade III or IV serious adverse events were seen. One-year estimated rates were numerically higher with HBO, for example overall survival 73% versus 56% and local recurrence-free survival 95% versus 78%, but the differences were not statistically significant. Tumor resection was linked to radionecrosis and to overall survival, and higher GPA was linked to overall survival (p less than 0.05 for these).
What This Means for Canadian Patients
For people with brain metastases, this study shows that giving hyperbaric oxygen shortly before radiosurgery could be done in a small group without an evident increase in radiation necrosis or other serious adverse events. It does not show that HBO improves tumor control or survival, because the differences seen were not statistically significant. Anyone considering this should discuss it with their radiation oncology team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study was small, used historical controls instead of random assignment, and found no statistically significant differences between groups, so it cannot show whether HBO helps or harms outcomes.